Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease?
暂无分享,去创建一个
[1] P. Vanhoutte,et al. Endothelium‐derived relaxing and contracting factors , 1989, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[2] W. Waldhäusl,et al. Effect of endothelin-1 in man. , 1990, Circulation.
[3] F. Fyhrquist,et al. Tissue distribution and half-life of 125I-endothelin in the rat: importance of pulmonary clearance. , 1990, Biochemical and Biophysical Research Communications - BBRC.
[4] D. Stewart,et al. Functional state of the endothelium determines the response to endothelin in the coronary circulation. , 1990, Cardiovascular research.
[5] A. Malik,et al. Endothelin-like pulmonary vasoconstrictor peptide release by alpha-thrombin. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[6] P. Nicod,et al. Primary pulmonary hypertension. The risk and benefit of lung biopsy. , 1989, Circulation.
[7] J. Pernow,et al. Increased plasma levels of endothelin-like immunoreactivity during endotoxin administration in the pig. , 1989, Acta physiologica Scandinavica.
[8] J. C. Ross,et al. Primary pulmonary hypertension: a look at the future. , 1989, Journal of the American College of Cardiology.
[9] J. Pittet,et al. Increased plasma and pulmonary lymph levels of endothelin during endotoxin shock. , 1989, European journal of pharmacology.
[10] D. Stewart,et al. Immunoreactive endothelin in human plasma: marked elevations in patients in cardiogenic shock. , 1989, Biochemical and biophysical research communications.
[11] M. Yanagisawa,et al. The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[12] T. Hauth,et al. Endothelin produces pulmonary vasoconstriction and systemic vasodilation. , 1989, Journal of applied physiology.
[13] E. K. Weir,et al. Etiologic mechanisms in primary pulmonary hypertension , 1989 .
[14] J. Vane,et al. Endothelin‐1 Releases Eicosanoids from Rabbit Isolated Perfused Kidney and Spleen , 1989, Journal of cardiovascular pharmacology.
[15] J. Vane,et al. Endothelin‐1 and Endothelin‐3 Release EDRF from Isolated Perfused Arterial Vessels of the Rat and Rabbit , 1989, Journal of Cardiovascular Pharmacology.
[16] S. Douglas,et al. Pressor Effects of Endothelin‐1 and Some Analogs in the Perfused Superior Mesenteric Arterial Bed of the Rat , 1989, Journal of Cardiovascular Pharmacology.
[17] D. Hosford,et al. Effect of Endothelin‐1 on Blood Pressure and Bronchopulmonary System of the Guinea Pig , 1989, Journal of Cardiovascular Pharmacology.
[18] J. Vane,et al. The Fate of Radioiodinated Endothelin‐1 and Endothelin‐3 in the Rat , 1989, Journal of cardiovascular pharmacology.
[19] B. Meyrick,et al. Endotoxin-induced pulmonary endothelial injury. , 1989, Progress in clinical and biological research.
[20] K. Nolop,et al. Endothelin‐1 from Pulmonary Artery and Micro vessels Acts on Vascular and Airway Smooth Muscle , 1989, Journal of Cardiovascular Pharmacology.
[21] J. Vane,et al. Pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium-derived relaxing factor. , 1988, Proceedings of the National Academy of Sciences of the United States of America.
[22] Sadao Kimura,et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells , 1988, Nature.
[23] M. Lewis,et al. Endothelium-derived relaxing factor. , 1988, Journal of the American College of Cardiology.
[24] E H Bergofsky,et al. Primary pulmonary hypertension. A national prospective study. , 1987, Annals of internal medicine.
[25] B. Groves,et al. The case for treatment of selected patients with primary pulmonary hypertension. , 1986, The American review of respiratory disease.
[26] R. Furchgott,et al. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine , 1980, Nature.
[27] J. Vane,et al. Pharmacology and endogenous roles of prostaglandin endoperoxides, thromboxane A2, and prostacyclin. , 1978, Pharmacological reviews.
[28] P. Wood. PULMONARY HYPERTENSION WITH SPECIAL REFERENCE TO THE VASOCONSTRICTIVE FACTOR* , 1958, British heart journal.
[29] D. Dresdale,et al. Primary pulmonary hypertension. I. Clinical and hemodynamic study. , 1951, The American journal of medicine.